US President Barack Obama with Indian Prime Minister Manmohan Singh. Official White House Photo by Pete Souza
India’s drug patent policy has been slammed by US companies who are insisting that action be taken in order to improve trade relations.
The rest of this article is locked for subscribers only. Please login to continue reading.
If you don't have a login, you will need to purchase a subscription to gain access to this article, including all our online content. Please use this link and follow the steps.
For multi-user price options, or to check if your company has an existing subscription to us that we can add you to for FREE, please email Atif Choudhury at email@example.com
US, patent, drugs, pharmaceuticals, evergreening, compulsory licence, AFTI, India, US